What are the main functions and indications of ivonib tablets?

Ivosidenib/Ivosidenib (Ivosidenib) is an oral small molecule targeted drug targeting IDH1 gene mutations. As an isocitrate dehydrogenase-1 (IDH1) inhibitor, its emergence provides new ideas for precise treatment of a variety of malignant tumors carrying IDH1 mutations. Under normal circumstances, the IDH1 enzyme participates in cellular metabolic processes, but in a mutated state, the enzyme abnormally produces the active metabolite 2-hydroxyglutarate (2-HG). This metabolite inhibits normal cell differentiation and leads to cell canceration. Ivonib has a clear anti-tumor effect by selectively inhibiting the activity of mutant IDH1 and reducing 2-HG levels, thus restoring the normal differentiation and apoptosis mechanisms of cells.

Ivonib was initially approved for the treatment of adult patients with IDH1 mutations in acute myeloid leukemia (AML), especially for two groups of people: First, newly diagnosed AML patients aged ≥75 years, or due to Individuals with comorbidities who are not suitable for intensive induction chemotherapy can be used alone or in combination with azacitidine; secondly, for AML patients who have relapsed or been refractory to standard treatment, ivonib has shown good remission rates and survival advantages in multiple clinical studies as a single-agent treatment. In addition, the drug is also gradually used in myelodysplastic syndromes (MDS), especially for patients with MDS who relapse after treatment or are ineffective in conventional treatments. Ivonib can reverse differentiation disorders and help some patients achieve improved hematology and even complete bone marrow remission. It is one of the important attempts in the precise treatment of MDS.

In addition to hematological diseases, the application of ivonib in solid tumors has also attracted much attention, especially in the field of locally advanced or metastatic cholangiocarcinoma (CCA). About 10%–20% of patients with cholangiocarcinoma have IDH1 mutations. Against the backdrop of limited efficacy of traditional chemotherapy, ivosidenib provides a new treatment option for this population. According to the results of the ClarIDHy clinical study, ivonib significantly prolonged progression-free survival in patients with cholangiocarcinoma who failed first-line treatment. It also showed good safety and controllable side effects, including fatigue, diarrhea, nausea, QT interval prolongation, etc., which can usually be alleviated by adjusting the dose.

Reference: https://www.tibsovo.com/